Back to trial details

Intake questionnaire

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Applying to University of Oklahoma Health Sciences Center · Oklahoma City, Oklahoma

Answer a few short questions to share with the research team.

0 of 3 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Anatomic Stage III Breast Cancer AJCC v8?
3. Are you able to travel to Oklahoma City for study visits?